Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Dermira Inc Cm ST (DERM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Pre-Market Technical Scan on Biotech Equities -- Spectrum Pharma, Jazz Pharma, Intra-Cellular Therapies, and Dermira

In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on SPPI, JAZZ, ITCI, and DERM which is a click away at http://www.wallstequities.com/registration...

SPPI : 19.00 (-2.16%)
ITCI : 18.06 (-4.29%)
DERM : 26.96 (-1.75%)
JAZZ : 149.80 (-0.26%)
Dermira to Present at Upcoming Investor Conferences in November

Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with...

DERM : 26.96 (-1.75%)
Dermira Reports Third Quarter 2017 Financial Results and Announces that FDA Accepts New Drug Application for Glycopyrronium Tosylate for the Treatment of Patients with Primary Axillary Hyperhidrosis

- FDA decision on New Drug Application expected by June 30, 2018

DERM : 26.96 (-1.75%)
Dermira and UCB Agree to End Collaboration Agreement for CIMZIA

-- Dermira to transition development and commercialization responsibility for CIMZIA (certolizumab pegol) in psoriasis back to UCB

DERM : 26.96 (-1.75%)
Corporate News Blog - Dermira Highlights Results from ARIDO Study for Assessment of Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis Patients

LONDON, UK / ACCESSWIRE / October 16, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Dermira, Inc. (NASDAQ: DERM), following which we have published...

DERM : 26.96 (-1.75%)
Dermira Highlights New Long-Term Safety Data for Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis at Fall Clinical Dermatology Conference

- Daily treatment with glycopyrronium tosylate in the Phase 3, open-label ARIDO trial was generally well-tolerated during 44 weeks of treatment

DERM : 26.96 (-1.75%)
Dermira, Inc. (DERM) Soars: Stock Adds 5.3% in Session

Dermira, Inc. (DERM) saw its shares rise over 5% on the day.

DERM : 26.96 (-1.75%)
MEIP : 2.19 (-7.20%)
Dermira Completes Patient Enrollment in Two Phase 3 Pivotal Trials of Olumacostat Glasaretil for the Treatment of Acne Vulgaris

- Phase 3 pivotal trials enrolled a total of 1,503 patients

DERM : 26.96 (-1.75%)
Dermira to Present at Cantor Fitzgerald Global Healthcare Conference

Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with...

DERM : 26.96 (-1.75%)
Biotech Stocks on Investors' Radar -- Clovis Oncology, Dermira, Editas Medicine, and Endocyte

If you want a Stock Review on CLVS, DERM, EDIT, or ECYT then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Thursday, September 14, 2017, US markets...

DERM : 26.96 (-1.75%)
CLVS : 55.41 (-6.10%)
ECYT : 3.80 (-6.40%)
EDIT : 30.02 (-6.19%)
Dermira Announces Early Termination of the Hart-Scott-Rodino Waiting Period for License to Lebrikizumab

Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with...

DERM : 26.96 (-1.75%)
New CIMZIA(R) (certolizumab pegol) Findings Presented at European Academy of Dermatology and Venereology (EADV) Congress

-- Presentations included the first 48-week data from the CIMPASI-1 and CIMPASI-2 psoriasis trials, and re-randomized data through 48 weeks from the CIMPACT psoriasis trial

DERM : 26.96 (-1.75%)
Dermira Presents New Data Showing Impact of Primary Axillary Hyperhidrosis on Patients

-- People suffering from primary axillary hyperhidrosis (excessive underarm sweating beyond what is needed to maintain normal body temperature) report that the condition has a significant impact on their...

DERM : 26.96 (-1.75%)
Dermira Presents New Data on Late-Stage Programs at Leading European Dermatology Congress

-- New findings from the glycopyrronium tosylate Phase 3 program highlight potential benefits of the investigational treatment and the impact of primary axillary hyperhidrosis on patients' daily activities...

DERM : 26.96 (-1.75%)
28.3% Return Seen to Date on SmarTrend Dermira Call (DERM)

SmarTrend identified a Downtrend for Dermira (NASDAQ:DERM) on April 21st, 2017 at $32.77. In approximately 5 months, Dermira has returned 28.35% as of today's recent price of $23.48.

DERM : 26.96 (-1.75%)
26.5% Return Seen to Date on SmarTrend Dermira Call (DERM)

SmarTrend identified a Downtrend for Dermira (NASDAQ:DERM) on April 21st, 2017 at $32.77. In approximately 4 months, Dermira has returned 26.49% as of today's recent price of $24.09.

DERM : 26.96 (-1.75%)
Best Relative Performance in the Pharmaceuticals Industry Detected in Shares of Horizon Pharma P (HZNP, MDCO, COLL, DERM, OCUL)

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...

COLL : 21.13 (+5.54%)
DERM : 26.96 (-1.75%)
HZNP : 14.62 (-3.69%)
MDCO : 25.67 (-6.69%)
OCUL : 5.30 (-5.36%)
Biotech Stocks on Investors' Radar -- Dermira, Endocyte, FibroGen, and Global Blood Therapeutics

If you want a Stock Review on DERM, ECYT, FGEN, or GBT then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Wednesday, August 10, 2017, US markets...

DERM : 26.96 (-1.75%)
GBT : 52.10 (-7.95%)
ECYT : 3.80 (-6.40%)
FGEN : 47.80 (-3.43%)
Dermira Enters into Agreement to License Exclusive, Worldwide Rights to Lebrikizumab

- Dermira plans to develop and commercialize lebrikizumab, a monoclonal antibody targeting IL-13, for moderate-to-severe atopic dermatitis

DERM : 26.96 (-1.75%)
UCB and Dermira Announce U.S. and EU Regulatory Submissions for CIMZIA(R) (certolizumab pegol) for the treatment of Moderate-to-Severe Chronic Plaque Psoriasis

-- The regulatory submissions for this new indication seek to expand the use of CIMZIA for the treatment of patients with moderate-to-severe chronic plaque psoriasis

DERM : 26.96 (-1.75%)

Van Meerten Stock Picks

My 5 Favorite Mid Cap Stocks
This morning I wanted to find 5 Mid Cap stocks that had great returns over the past year and still seem to have some juice left.
KBH -1.63 , IPGP +2.02 , FSLR -2.19 , NVR -17.23 , SGMS +0.25
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH18 +0.39%) are up +0.41% at a fresh record nearest-futures high as growth optimism fuels gains in global equity markets. Gains in technology stocks are leading the overall market higher as... Read More

Chart of the Day

Chart of the Day

Audentes Therapeutcs (BOLD) is rhe Barchart Chart of the Day.  The biomedical company has a Trend Spotter buy signal, a Weighted Alpha of 174.58+ and gained 111.74% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures bounced back from Friday’s bearish USDA reports to close Tuesday with gains of 2 cents in most nearby contracts. The weekly Export Inspections report indicated just 584,389 MT of corn was shipped during the week of Jan 11. That is ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.